Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4871)
All Articles published online
|
Dec 15, 2004 (publication date) through Nov 8, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Lu W, Zheng S, Li XF, Huang JJ, Zheng X, Li Z. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: A pilot phase II clinical trial. World J Gastroenterol 2004; 10(24): 3634-3638 [PMID: 15534920 DOI: 10.3748/wjg.v10.i24.3634] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v10/i24/3634.htm |
| Number | Citing Articles |
| 1 |
Ajit S. Narang, Sailesh Varia. Role of tumor vascular architecture in drug delivery. Advanced Drug Delivery Reviews 2011; 63(8): 640 doi: 10.1016/j.addr.2011.04.002
|
| 2 |
Yalei Zhang, Ling Qian, Kun Chen, Sijia Gu, Zhiqiang Meng, Jia Wang, Ye Li, Peng Wang. Oncolytic adenovirus in treating malignant ascites: A phase II trial and longitudinal single-cell study. Molecular Therapy 2024; 32(6): 2000 doi: 10.1016/j.ymthe.2024.04.029
|
| 3 |
Audrey Choi, Michael O’Leary, Yuman Fong, Nanhai Chen. From Benchtop to Bedside: A Review of Oncolytic Virotherapy. Biomedicines 2016; 4(3): 18 doi: 10.3390/biomedicines4030018
|
| 4 |
Nasser Hashemi Goradel, Nasir Mohajel, Ziba Veisi Malekshahi, Samira Jahangiri, Masoud Najafi, Bagher Farhood, Keywan Mortezaee, Babak Negahdari, Arash Arashkia. Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches. Journal of Cellular Physiology 2019; 234(6): 8636 doi: 10.1002/jcp.27850
|
| 5 |
Biyun Cun, Xin Song, Renbing Jia, Xiaoping Zhao, Haibo Wang, Shengfang Ge, Xianqun Fan. Combination of oncolytic adenovirus and dacarbazine enhances antitumor ability against uveal melanoma cells via cell cycle block. Cancer Biology & Therapy 2012; 13(2): 77 doi: 10.4161/cbt.13.2.18436
|
| 6 |
Changqing Su, Hui Cao, Shuping Tan, Yao Huang, Xiaoyuan Jia, Lixin Jiang, Kai Wang, Ying Chen, Ju Long, Xinyuan Liu, Mengchao Wu, Xiaobing Wu, Qijun Qian. Toxicology Profiles of a Novel p53-Armed Replication-Competent Oncolytic Adenovirus in Rodents, Felids, and Nonhuman Primates. Toxicological Sciences 2008; 106(1): 242 doi: 10.1093/toxsci/kfn168
|
| 7 |
Michael Phan, Margaret F. Watson, Tommy Alain, Jean-Simon Diallo. Oncolytic Viruses on Drugs: Achieving Higher Therapeutic Efficacy. ACS Infectious Diseases 2018; 4(10): 1448 doi: 10.1021/acsinfecdis.8b00144
|
| 8 |
Masayuki Kurooka, Yasufumi Kaneda. Inactivated Sendai Virus Particles Eradicate Tumors by Inducing Immune Responses through Blocking Regulatory T Cells. Cancer Research 2007; 67(1): 227 doi: 10.1158/0008-5472.CAN-06-1615
|
| 9 |
Chao Fang, Gaozhe Xiao, Taixia Wang, Li Song, Bo Peng, Bin Xu, Kun Zhang. Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy. Research 2023; 6 doi: 10.34133/research.0108
|
| 10 |
Danni Lin, Yinan Shen, Tingbo Liang. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduction and Targeted Therapy 2023; 8(1) doi: 10.1038/s41392-023-01407-6
|
| 11 |
Noga Lipschitz, Brian R. Earl, Timothy P. Cripe, Ravi N. Samy. Oncolytic virotherapy: a potential therapeutic approach for cholesteatoma. Current Opinion in Otolaryngology & Head & Neck Surgery 2020; 28(5): 281 doi: 10.1097/MOO.0000000000000651
|
| 12 |
Pei-Hsin Cheng, Stephen Wechman, Kelly McMasters, Heshan Zhou. Oncolytic Replication of E1b-Deleted Adenoviruses. Viruses 2015; 7(11): 5767 doi: 10.3390/v7112905
|
| 13 |
Lihong Wang, Louisa S Chard Dunmall, Zhenguo Cheng, Yaohe Wang. Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment. Journal for ImmunoTherapy of Cancer 2022; 10(5): e004167 doi: 10.1136/jitc-2021-004167
|
| 14 |
Ta-Chiang Liu, Evanthia Galanis, David Kirn. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nature Clinical Practice Oncology 2007; 4(2): 101 doi: 10.1038/ncponc0736
|
| 15 |
Patrycja J Lech, Stephen J Russell. Use of attenuated paramyxoviruses for cancer therapy. Expert Review of Vaccines 2010; 9(11): 1275 doi: 10.1586/erv.10.124
|
| 16 |
Ding Wei, Jing Xu, Xin-Yuan Liu, Zhi-Nan Chen, Huijie Bian. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China. Human Gene Therapy 2018; 29(2): 151 doi: 10.1089/hum.2017.212
|
| 17 |
Richard Kolade Omole, Oluwaseyi Oluwatola, Millicent Tambari Akere, Joseph Eniafe, Elizabeth Oladoyin Agboluaje, Oluwafemi Bamidele Daramola, Yemisi Juliet Ayantunji, Temiloluwa Ifeoluwa Omotade, Nkem Torimiro, Modupe Stella Ayilara, Oluwole Isaac Adeyemi, Olubusola Sajanat Salinsile. Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.1082797
|
| 18 |
M Shiina, M D Lacher, C Christian, W M Korn. RNA interference-mediated knockdown of p21WAF1 enhances anti-tumor cell activity of oncolytic adenoviruses. Cancer Gene Therapy 2009; 16(11): 810 doi: 10.1038/cgt.2009.29
|
| 19 |
E. V. Melnikova, O. A. Rachinskaya, V. A. Merkulov. Advanced Therapy Medicines Based on Oncolytic Viruses (Part I: Development and Authorisation of Products in China). The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products 2021; 11(3): 148 doi: 10.30895/1991-2919-2021-11-148-159
|
| 20 |
Jonathan M. Goodwin, Anthony D. Schmitt, Christopher M. McGinn, Bryan C. Fuchs, Darshini Kuruppu, Kenneth K. Tanabe, Michael Lanuti. Angiogenesis Inhibition Using an Oncolytic Herpes Simplex Virus Expressing Endostatin in a Murine Lung Cancer Model. Cancer Investigation 2012; 30(3): 243 doi: 10.3109/07357907.2012.654870
|
| 21 |
Palaniyandi Muthukutty, So Young Yoo. Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective. Viruses 2023; 15(8): 1645 doi: 10.3390/v15081645
|
| 22 |
Bryan Oronsky, Brian Gastman, Anthony P. Conley, Christopher Reid, Scott Caroen, Tony Reid. Oncolytic Adenoviruses: The Cold War against Cancer Finally Turns Hot. Cancers 2022; 14(19): 4701 doi: 10.3390/cancers14194701
|
| 23 |
K. Devaraja. Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma. Pharmaceutical Medicine 2019; 33(4): 269 doi: 10.1007/s40290-019-00288-x
|
| 24 |
Stephen Wechman, Xiao-Mei Rao, Kelly McMasters, Heshan Zhou. Adenovirus with DNA Packaging Gene Mutations Increased Virus Release. Viruses 2016; 8(12): 333 doi: 10.3390/v8120333
|
| 25 |
Su Shao, Peng-Fei Xu, Xiao-Ping Zhan. Effects of H101 on proliferation, migration, and apoptosis of gastric cancer cells and underlying mechanisms. World Chinese Journal of Digestology 2022; 30(18): 803 doi: 10.11569/wcjd.v30.i18.803
|
| 26 |
Ramon Alemany. Cancer selective adenoviruses. Molecular Aspects of Medicine 2007; 28(1): 42 doi: 10.1016/j.mam.2006.12.002
|
| 27 |
Mari Raki, Merja Särkioja, Renee A. Desmond, Dung-Tsa Chen, Ralf Bützow, Akseli Hemminki, Anna Kanerva. Oncolytic adenovirus Ad5/3-Δ24 and chemotherapy for treatment of orthotopic ovarian cancer. Gynecologic Oncology 2008; 108(1): 166 doi: 10.1016/j.ygyno.2007.09.013
|
| 28 |
Pin-I Huang, Ju-Fang Chang, David H. Kirn, Ta-Chiang Liu. Targeted genetic and viral therapy for advanced head and neck cancers. Drug Discovery Today 2009; 14(11-12): 570 doi: 10.1016/j.drudis.2009.03.008
|
| 29 |
JUNFEN MA, JIMIN ZHAO, JING LU, YANAN JIANG, HONGYAN YANG, PEI LI, MINGYAO ZHAO, KANGDONG LIU, ZIMING DONG. Coxsackievirus and adenovirus receptor promotes antitumor activity of oncolytic adenovirus H101 in esophageal cancer. International Journal of Molecular Medicine 2012; 30(6): 1403 doi: 10.3892/ijmm.2012.1133
|
| 30 |
O. Hemminki, R. Immonen, J. Närväinen, A. Kipar, J. Paasonen, K.T. Jokivarsi, H. Yli‐Ollila, P. Soininen, K. Partanen, T. Joensuu, S. Parvianen, S.K. Pesonen, A. Koski, M. Vähä‐Koskela, V. Cerullo, S. Pesonen, O.H. Gröhn, A. Hemminki. In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders. International Journal of Cancer 2014; 134(12): 2878 doi: 10.1002/ijc.28615
|
| 31 |
Talal Alzahrani, Raluca Eftimie, Dumitru Trucu. Multiscale modelling of cancer response to oncolytic viral therapy. Mathematical Biosciences 2019; 310: 76 doi: 10.1016/j.mbs.2018.12.018
|
| 32 |
Chen Liu, Bin Sun, Ni An, Weifeng Tan, Lu Cao, Xiangji Luo, Yong Yu, Feiling Feng, Bin Li, Mengchao Wu, Changqing Su, Xiaoqing Jiang. Inhibitory effect of Survivin promoter‐regulated oncolytic adenovirus carrying P53 gene against gallbladder cancer. Molecular Oncology 2011; 5(6): 545 doi: 10.1016/j.molonc.2011.10.001
|
| 33 |
Kyle G. Potts, Mary M. Hitt, Ronald B. Moore. Oncolytic Viruses in the Treatment of Bladder Cancer. Advances in Urology 2012; 2012: 1 doi: 10.1155/2012/404581
|
| 34 |
Soo-Hyun Kim, Crispin R Dass. p53-targeted cancer pharmacotherapy: move towards small molecule compounds. Journal of Pharmacy and Pharmacology 2011; 63(5): 603 doi: 10.1111/j.2042-7158.2010.01248.x
|
| 35 |
Chao-Bin He, Xiang-Ming Lao, Xiao-Jun Lin. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study. Chinese Journal of Cancer 2017; 36(1) doi: 10.1186/s40880-017-0227-2
|
| 36 |
Xiao-jun Lin, Qi-jiong Li, Xiang-ming Lao, Han Yang, Sheng-ping Li. Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC). BMC Cancer 2015; 15(1) doi: 10.1186/s12885-015-1715-x
|
| 37 |
Daniel Cervantes-García;, Rocío Ortiz-López;, Netzahualcoyotl Mayek-Pérez;, Augusto Rojas-Martínez;. Oncolytic virotherapy. Annals of Hepatology 2008; 7(1): 34 doi: 10.1016/S1665-2681(19)31885-X
|
| 38 |
Xiangxing Liu, Jiaojiao Zhang, Keqing Feng, Simin Wang, Liming Chen, Suping Niu, Qian Lu, Yi Fang. Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.1023533
|
| 39 |
Gerard V. Walls, Manuel C. Lemos, Mahsa Javid, Miriam Bazan-Peregrino, Jeshmi Jeyabalan, Anita A.C. Reed, Brian Harding, Damian J. Tyler, Daniel J. Stuckey, Sian Piret, Paul T. Christie, Olaf Ansorge, Kieran Clarke, Len Seymour, Rajesh V. Thakker.
MEN1 Gene Replacement Therapy Reduces Proliferation Rates in a Mouse Model of Pituitary Adenomas. Cancer Research 2012; 72(19): 5060 doi: 10.1158/0008-5472.CAN-12-1821
|
| 40 |
Megan Grundy, Constantin Coussios, Robert Carlisle. Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer. Expert Opinion on Drug Delivery 2016; 13(7): 999 doi: 10.1517/17425247.2016.1167036
|
| 41 |
Mari Raki, Daniel T. Rein, Anna Kanerva, Akseli Hemminki. Gene Transfer Approaches for Gynecological Diseases. Molecular Therapy 2006; 14(2): 154 doi: 10.1016/j.ymthe.2006.02.019
|
| 42 |
Tanja Hakkarainen, Maria Rajecki, Mirkka Sarparanta, Mikko Tenhunen, Anu J. Airaksinen, Renée A. Desmond, Kalevi Kairemo, Akseli Hemminki. Targeted Radiotherapy for Prostate Cancer with an Oncolytic Adenovirus Coding for Human Sodium Iodide Symporter. Clinical Cancer Research 2009; 15(17): 5396 doi: 10.1158/1078-0432.CCR-08-2571
|
| 43 |
Karoly Toth, William S. M. Wold. Increasing the Efficacy of Oncolytic Adenovirus Vectors. Viruses 2010; 2(9): 1844 doi: 10.3390/v2091844
|
| 44 |
Alexander Baker, Carmen Aguirre-Hernández, Gunnel Halldén, Alan Parker. Designer Oncolytic Adenovirus: Coming of Age. Cancers 2018; 10(6): 201 doi: 10.3390/cancers10060201
|
| 45 |
Kelley A. Parato, Donna Senger, Peter A. J. Forsyth, John C. Bell. Recent progress in the battle between oncolytic viruses and tumours. Nature Reviews Cancer 2005; 5(12): 965 doi: 10.1038/nrc1750
|
| 46 |
Christopher Y Woo, Takuya Osada, Timothy M Clay, H Kim Lyerly, Michael A Morse. Recent clinical progress in virus-based therapies for cancer. Expert Opinion on Biological Therapy 2006; 6(11): 1123 doi: 10.1517/14712598.6.11.1123
|
| 47 |
Ellen A. M. Schenk‐Braat, Marjolein M. K. B. van Mierlo, Gerard Wagemaker, Chris H. Bangma, Leonie C. M. Kaptein. An inventory of shedding data from clinical gene therapy trials. The Journal of Gene Medicine 2007; 9(10): 910 doi: 10.1002/jgm.1096
|
| 48 |
Junfen Ma, Nan Li, Jimin Zhao, Jing Lu, Yanqiu Ma, Qinghua Zhu, Ziming Dong, Kangdong Liu, Liang Ming. Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo. Oncology Letters 2017; 13(6): 4868 doi: 10.3892/ol.2017.6069
|
| 49 |
Alireza Shahryari, Marie Saghaeian Jazi, Saeed Mohammadi, Hadi Razavi Nikoo, Zahra Nazari, Elaheh Sadat Hosseini, Ingo Burtscher, Seyed Javad Mowla, Heiko Lickert. Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders. Frontiers in Genetics 2019; 10 doi: 10.3389/fgene.2019.00868
|
| 50 |
Adel H. Jebar, Richard G. Vile, Alan A. Melcher, Stephen Griffin, Peter J. Selby, Fiona Errington-Mais. Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma. Journal of General Virology 2015; 96(7): 1533 doi: 10.1099/vir.0.000098
|
| 51 |
Shruthi Naik, Stephen J Russell. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opinion on Biological Therapy 2009; 9(9): 1163 doi: 10.1517/14712590903170653
|
| 52 |
Niloofar Kiaheyrati, Abouzar Babaei, Reza Ranji, Ensiyeh Bahadoran, Shiva Taheri, Zahra Farokhpour. Cancer therapy with the viral and bacterial pathogens: The past enemies can be considered the present allies. Life Sciences 2024; 349: 122734 doi: 10.1016/j.lfs.2024.122734
|
| 53 |
Otto Hemminki, Akseli Hemminki. Gene Therapy of Cancer. 2014; : 153 doi: 10.1016/B978-0-12-394295-1.00011-1
|
| 54 |
Amir Fakhari, J. Anand Subramony. Engineered in-situ depot-forming hydrogels for intratumoral drug delivery. Journal of Controlled Release 2015; 220: 465 doi: 10.1016/j.jconrel.2015.11.014
|
| 55 |
Masayuki KUROOKA, Yasufumi KANEDA. Anticancer Immunotherapy using Inactivated Sendai Virus Particles. Uirusu 2007; 57(1): 19 doi: 10.2222/jsv.57.19
|
| 56 |
Chaobin He, Yu Zhang, Xiaojun Lin. Increased Overall Survival and Decreased Cancer-Specific Mortality in Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization and Human Adenovirus Type-5 Combination Therapy: a Competing Risk Analysis. Journal of Gastrointestinal Surgery 2018; 22(6): 989 doi: 10.1007/s11605-018-3703-3
|
| 57 |
Simone Mocellin, Carlo R. Rossi, Alba Brandes, Donato Nitti. Adult soft tissue sarcomas: Conventional therapies and molecularly targeted approaches. Cancer Treatment Reviews 2006; 32(1): 9 doi: 10.1016/j.ctrv.2005.10.003
|
| 58 |
L. Yi, Z. Ning, L. Xu, Y. Shen, X. Zhu, W. Yu, J. Xie, Z. Meng. The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study. ESMO Open 2024; 9(2): 102239 doi: 10.1016/j.esmoop.2024.102239
|
| 59 |
Man Yao, Simo Cheng, Xiaofeng Zhai, Hetong Zhao, Jing Hong, Xiaoyan Li, Yongbin Meng, Wei Chen, Ye Liu. Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis. Applied Bionics and Biomechanics 2022; 2022: 1 doi: 10.1155/2022/9084852
|
| 60 |
Yalei Zhang, Ling Qian, Kun Chen, Sijia Gu, Jia Wang, Zhiqiang Meng, Ye Li, Peng Wang. Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response. Molecular Therapy - Oncolytics 2022; 25: 31 doi: 10.1016/j.omto.2022.03.003
|
| 61 |
Dörthe Masemann, Yvonne Boergeling, Stephan Ludwig. Employing RNA viruses to fight cancer: novel insights into oncolytic virotherapy. Biological Chemistry 2017; 398(8): 891 doi: 10.1515/hsz-2017-0103
|
| 62 |
Sufi Mary Thomas, Jennifer Rubin Grandis. The Current State of Head and Neck Cancer Gene Therapy. Human Gene Therapy 2009; 20(12): 1565 doi: 10.1089/hum.2009.163
|
| 63 |
Ngoc Kim Phan. Biological therapy: a new age of cancer treatment. Biomedical Research and Therapy 2014; 1(2) doi: 10.7603/s40730-014-0006-5
|
| 64 |
Maria Eugenia Davola, Karen Louise Mossman. Oncolytic viruses: how “lytic” must they be for therapeutic efficacy?. OncoImmunology 2019; 8(6): e1581528 doi: 10.1080/2162402X.2019.1596006
|
| 65 |
Stephen Wechman, Xiao-Mei Rao, Pei-Hsin Cheng, Jorge Gomez-Gutierrez, Kelly McMasters, H. Zhou. Development of an Oncolytic Adenovirus with Enhanced Spread Ability through Repeated UV Irradiation and Cancer Selection. Viruses 2016; 8(6): 167 doi: 10.3390/v8060167
|
| 66 |
Jia-Li Zhao, Bi-Lin Lin, Chen Luo, Yan-ling Yi, Peng Huang, Yu Chen, Sha Zhao, Zhen-Jie Huang, Xin-Yi Ma, Long Huang. Challenges and strategies toward oncolytic virotherapy for leptomeningeal metastasis. Journal of Translational Medicine 2024; 22(1) doi: 10.1186/s12967-024-05794-4
|
| 67 |
Menghan Gao, Erik Yngve, Di Yu, Chuan Jin. A qPCR-Based Method for Quantification of RCA Contaminants in Oncolytic Adenovirus Products. Frontiers in Molecular Biosciences 2022; 9 doi: 10.3389/fmolb.2022.883249
|
| 68 |
Xiaoyu Zhang, Tianyi Ding, Fan Yang, Haowen Xu, Jixing Zhang, Yiran Bai, Yibing Shi, Jiaqi Yang, Chaoqun Chen, He Zhang. Induced dual-target rebalance simultaneously enhances efficient therapeutical efficacy in tumors. Cell Death Discovery 2024; 10(1) doi: 10.1038/s41420-024-02018-y
|
| 69 |
Qiong Lin, Deng-Gao Wang, Zhu-Qin Zhang, De-Pei Liu. Applications of Virus Vector–Mediated Gene Therapy in China. Human Gene Therapy 2018; 29(2): 98 doi: 10.1089/hum.2017.238
|
| 70 |
Christos Fountzilas, Sukeshi Patel, Devalingam Mahalingam. Review: Oncolytic virotherapy, updates and future directions. Oncotarget 2017; 8(60): 102617 doi: 10.18632/oncotarget.18309
|
| 71 |
Ran Zhang, Yanxin Cui, Xin Guan, Xiangjun Jiang. A Recombinant Human Adenovirus Type 5 (H101) Combined With Chemotherapy for Advanced Gastric Carcinoma: A Retrospective Cohort Study. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.752504
|
| 72 |
Yuguo Zhang, Musa Gabere, Mika A. Taylor, Camila C. Simoes, Chelsae Dumbauld, Oumar Barro, Mulu Z. Tesfay, Alicia L. Graham, Khandoker Usran Ferdous, Alena V. Savenka, Jean Christopher Chamcheu, Charity L. Washam, Duah Alkam, Allen Gies, Stephanie D. Byrum, Matteo Conti, Steven R. Post, Thomas Kelly, Mitesh J. Borad, Martin J. Cannon, Alexei Basnakian, Bolni M. Nagalo. Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.1042250
|
| 73 |
Daniel T. Rein, Anne Volkmer, Gerd Bauerschmitz, Ines M. Beyer, Wolfgang Janni, Markus C. Fleisch, Anne Kathrin Welter, Dirk Bauerschlag, Thomas Schöndorf, Martina Breidenbach. Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer. Journal of Cancer Research and Clinical Oncology 2012; 138(4): 603 doi: 10.1007/s00432-011-1135-5
|
| 74 |
J P Hughes, G Alusi, Y Wang. Viral gene therapy for head and neck cancer. The Journal of Laryngology & Otology 2015; 129(4): 314 doi: 10.1017/S0022215114003247
|
| 75 |
Nasser Hashemi Goradel, Arezoo Alizadeh, Shahnaz Hosseinzadeh, Mitra Taghipour, Zeinab Ghesmati, Arash Arashkia, Babak Negahdari. Oncolytic Virotherapy as Promising Immunotherapy Against Cancer: Mechanisms of Resistance to Oncolytic Viruses. Future Oncology 2022; 18(2): 245 doi: 10.2217/fon-2021-0802
|
| 76 |
Caihong Chen, Haiyan Fang, Yumei Rao, Peng Wu, Yang He, Ding Ma, Qinglei Gao. Preliminary evaluation of safety of conditionally replication adenovirus M4. Journal of Huazhong University of Science and Technology [Medical Sciences] 2012; 32(6): 893 doi: 10.1007/s11596-012-1054-y
|
| 77 |
Karoly Toth, Debanjan Dhar, William SM Wold. Oncolytic (replication-competent) adenoviruses as anticancer agents. Expert Opinion on Biological Therapy 2010; 10(3): 353 doi: 10.1517/14712590903559822
|
| 78 |
Joshua Del Papa, Robin Parks. Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents. Viruses 2017; 9(1): 13 doi: 10.3390/v9010013
|
| 79 |
|
| 80 |
Behnaz Taheri, Zeinab Zarei-Behjani, Abouzar Babaei, Fatemeh Matin Moradkhan. Extracellular Vesicles: a Trojan Horse Delivery Method for Systemic Administration of Oncolytic Viruses. Regenerative Engineering and Translational Medicine 2023; 9(4): 447 doi: 10.1007/s40883-023-00295-0
|
| 81 |
Xiao Yin Ma, Brett D. Hill, Trang Hoang, Fei Wen. Virus-inspired strategies for cancer therapy. Seminars in Cancer Biology 2022; 86: 1143 doi: 10.1016/j.semcancer.2021.06.021
|
| 82 |
Lizhi Li, Shixin Liu, Duoduo Han, Bin Tang, Jian Ma. Delivery and Biosafety of Oncolytic Virotherapy. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.00475
|